Dana Deupree, MD
Retina Specialist · Spring Hill, FLNPI 1083606198
Payments from drug & device makers
Across 928 payments — averaging $1595.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$534K
- Genentech, Inc.$359K
- Kyowa Kirin, Inc.$222K
- Eyepoint US, Inc.$182K
- AstraZeneca$59K
- Ocular Therapeutix, Inc.$45K
- plus $79K from 26 others
Across 25 payments — averaging $1882.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alimera Sciences, Inc.$47K
- Regeneron$273
What the payments were for
- Speaking & faculty fees$3,05931%
- Travel & lodging$6827%
- Food & beverage$6,01562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 440 | $533,976 |
| Genentech, Inc. | 117 | $359,174 |
| Kyowa Kirin, Inc. | 84 | $222,162 |
| Eyepoint US, Inc. | 17 | $182,144 |
| AstraZeneca | 3 | $59,472 |
| Ocular Therapeutix, Inc. | 12 | $44,505 |
| Grifols, S.A. | 50 | $30,830 |
| ANI Pharmaceuticals, Inc. | 19 | $22,446 |
| Apellis Pharmaceuticals, Inc. | 6 | $18,665 |
| Alimera Sciences, Inc. | 52 | $2,969 |
| Mallinckrodt Hospital Products Inc. | 37 | $903 |
| Alcon Research LLC | 1 | $682 |
| Genentech USA, Inc. | 14 | $432 |
| Biogen | 5 | $388 |
| Bausch & Lomb Americas Inc. | 9 | $286 |
| AbbVie(2 entities) | 13 | $228 |
| Mallinckrodt Enterprises LLC | 6 | $179 |
| Regeneron Healthcare Solutions, Inc. | 6 | $163 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $119 |
| Amgen(2 entities) | 6 | $111 |
| Notal Vision, Inc. | 5 | $109 |
| Harrow Eye, LLC | 4 | $104 |
| Astellas Pharma US Inc | 4 | $100 |
| Novartis | 4 | $74 |
| Kala Pharmaceuticals, Inc. | 2 | $43 |
| Dompe US, Inc. | 1 | $32 |
| Glaukos Corporation | 1 | $32 |
| Sun Pharmaceutical Industries Inc. | 1 | $27 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $20 |
| Oyster Point Pharma, Inc. | 1 | $19 |
| Coherus Oncology, Inc. | 1 | $17 |
| Alcon | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,480,426 in reported general payments places this provider in the 90th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 22 | $69,575 |
| VabysmoFaricimab-Svoa | 15 | $47,006 |
| Prednisolone Acetate | 337 | $12,135 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 39 | $4,642 |
| Latanoprost | 331 | $3,211 |
| Brimonidine Tartrate | 226 | $3,044 |
| Travoprost | 16 | $2,047 |
| Loteprednol Etabonate | 15 | $1,961 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 89 | $1,243 |
| Difluprednate | 12 | $1,154 |
| Timolol Maleate | 113 | $1,151 |
| Dexamethasone Sodium Phosphate | 12 | $564 |
| Ketorolac Tromethamine | 17 | $491 |
| Dorzolamide Hcl | 32 | $385 |
| ErythromycinErythromycin Base | 27 | $269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $163 | $69,57522 claims |
| Genentech USA, Inc.Vabysmo | $432 | $47,00615 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $119 | $1,96115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 118 retina specialist providers in Florida.
Other retina specialist in Spring Hill
- Shailesh GuptaDeerfield Beach$18.8M
- Vrinda HershbergerMelbourne$8.2M
- Sunil GuptaPensacola$8.1M
- Stuart BurgessPlantation$4.6M
- Eduardo UchiyamaFt Lauderdale$4.1M
- Drew BawcombeDeerfield Beach$2M
- Eric GuglielmoMerritt Island$1.5M
- Jason HandzaPinellas Park$1.3M
- Ashish SharmaFort Myers$994K
- Joseph WalkerFt Myers$615K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.